SlideShare a Scribd company logo
PRESENTED BY:
VISHNU.R.NAIR,
5TH YEAR PHARM.D,
NATIONAL COLLEGE OF PHARMACY(NCP).
GENERAL INTRODUCTION
Refer to tests, that provide OBJECTIVE & QUANTIFIABLE
measures of LUNG FUNCTION
Useful in the DIAGNOSIS, EVALUATION & MONITORING
of respiratory disease/s
Also help to evaluate :
a. Response/ efficacy of ongoing therapy
b. Side-effects of medications, that lead to pulmonary disease.
IMPORTANT USES OF PFTs???
 Include:
A. DIAGNOSIS:
- Clinical manifestations of respiratory disease
- Follow-up of historical/lab findings
- Disease effects on pulmonary function
- Drug-induced pulmonary disorders.
B. EVALUATION:
- Medico-legal issues
- Rehabilitation
C. MONITORING:
- Respiratory disease progression
- Prognosis
- Occupational/ environmental exposure to toxins
- Therapeutic drug effectiveness
- Drug effects on pulmonary function.
SPIROMETRY
- Test, that measures various aspects of breathing & lung function
- Standardization of spirometry  regulated by ATS & ERS guidelines
- PROCEDURE OF SPIROMETRY:
a. Patient  asked to breathe into a tube(mouth piece)
b. Mouth piece  connected to a machine(spirometer)
c. Spirometer  measures amount & flow of inhaled/ exhaled air
d. Physical forces of airflow + total amount of air inhaled/exhaled  converted by
transducers to electrical signals  displayed on a computer screen
e. Prior to conducting spirometry  the technique involved SHOULD BE
EXPLAINED & DEMONSTRATED TO THE PATIENT
f. Since spirometry results  depend on patient’s inhalation & exhalation 
importance of COMPLETELY FILLING & EMPYTING THE LUNGS OF AIR
during the test should be emphasized!!
g. Nose clips should be worn during the test(to prevent air loss through nose!)
Pulmonary function tests: A brief Insight- By RxVichuZ! :)
- There are 2 types of SPIROMETRY SYSTEMS:
A. OPEN-CIRCUIT SYSTEM:
- In this  patient has to INHALE BEFORE INSERTING THE MOUTH-PIECE
B. CLOSED-CIRCUIT SYSTEM:
- In this  mouthpiece is first inserted  patient takes several normal breaths,
before airflow is measured
- There are 2 TYPES of SPIROMETRY:
A. STATIC SPIROMETRY:
- Test, that is “VOLUME-BASED” & “SLOW”
B. DYNAMIC SPIROMETRY:
- Test, that is “TIME-BASED”
- Flow-dependant
- “FORCED”!!
SPIROMETRY
MEASUREMENTS
Include:
1. VITAL CAPACITY(VC)
2. FORCED EXPIRATORY VOLUME(FEV)
3. FORCED EXPIRATORY FLOW(FEF)
- Via SPIROMETRY  above values, & a FLOW-VOLUME CURVE are obtained
- FLOW-VOLUME CURVE:
a. Graphical representation of INSPIRATION & EXPIRATION
b. Also known as “flow-volume loops”.
VITAL CAPACITY:
- Includes:
a. FORCED VITAL CAPACITY(FVC)
b. SLOW VITAL CAPACITY(SVC)
- FVC  refers to total volume of air EXHALED as HARD & as FAST as possible
after a MAXIMAL INHALATION
- Obtained from “DYNAMIC SPIROMETRY”
- SVC  refers to total volume of air EXHALED as SLOW as possible, after a
MAXIMAL INHALATION
- SVC  obtained from “STATIC SPIROMETRY”.
- In patients with NORMAL AIRWAY FUNCTION  FVC &
SVC are usually similar
- In COPD patients  there is trivial divergence!
- During initial stages of COPD  FVC decreases before SVC
does!
FORCED EXPIRATORY VOLUME:
- Refers to the assessment of how much air a person can exhale during a FORCED
BREATH.
- Amounts of air exhaled may be measured after:
a. FEV0.5: 0.5 seconds
b. FEV1: 1 second(clinically significant, indicator of airway function!)
c. FEV3: 3 seconds
d. FEV6: 6 seconds, respectively.
- FEV1/FVC ratio  used to estimate presence & amount of obstruction inside
airways
- In normal individuals  exhalation is approximately 50 % of their FVC in the
first 0.5 seconds, 80% in 1 second & 98 % in 3 seconds.
- In patients with OBSTRUCTIVE DISEASE  there is a decreased ratio (ratio
varies based on obstruction severity).
- According to ATS(American Thoracic Society), EPS(European Respiratory
Society) & GOLD(Global Initiative for Chronic Obstructive Lung Disease)
guidelines  the following criteria is given for diagnosis & severity grading of
COPD:
a. If FEV1/FVC ratio < 70%  indicates chronic obstruction(DIAGNOSIS)
b. For SEVERITY GRADING  FEV1 values are noted:
• If FEV1 ≥ 80% : Mild-severity
• If FEV1 = 50-80% : Moderate severity
• If FEV1= 30-50% : Severe form of disease
• If FEV1< 30% : Very severe form of disease, respiratory failure.
FORCED EXPIRATORY FLOW:
- Measures AIRFLOW RATE during FORCED EXPIRATION
- Used to measure:
a. Flow of air in medium & small airways(bronchioles & terminal bronchioles)
b. To check for large obstructions in terminal bronchioles (as in acute severe
asthma).
PEAK EXPIRATORY FLOW RATE:
- Also known as “peak flow”
- Occurs within first milliseconds of expiratory flow
- Measures maximum airflow rate
- Measured using PEAK FLOW METERS
- Applications:
a. To evaluate for large airway obstruction
b. To determine severity of asthma exacerbation
- PEFR  preferred over SPIROMETRY during exacerbation preferential
benefit!!!
DISEASE FEV1/FVC FEV1 FVC RV TLC
COPD Decreased Decreased Normal/decrease
d
Normal/Increase
d
Normal/Increase
d
Obstructive
Lung
Disease(Reversi
ble & Stable)
Normal Normal Normal Normal Normal
Restrictive Lung
Disease
Normal/Increase
d
Decreased Decreased Decreased Decreased
Combined
Obstructive &
Restrictive
Decreased/norm
al
Decreased Decreased Increased,
normal/decrease
d
Decreased
BODY PLETHYSMOGRAPHY
& LUNG VOLUMES
 Body plethysmography  refers to the method used to obtain LUNG VOLUME
MEASURES
 Lung volumes  indicate the amount of gas present in the lungs at various
stages of inflation
 In body plethysmography  patient is asked to sit inside an airtight box  asked
to inhale & exhale against a closed shutter
 Inside the box  there will be a PRESSURE TRANSDUCER
 PRESSURE TRANSDUCER  measures pressure changes within the box during
respiration
 In other words  transducer measures the intrathoracic pressure generated
when the patient rapidly & forcefully puffs against the closed mouthpiece!!!
Pulmonary function tests: A brief Insight- By RxVichuZ! :)
- Above obtained details  interpreted into Boyle’s Law:
“ P1 * V1 = P2 * V2”, where
“P1”: Pressure inside the box, when the patient is seated(atmospheric pressure)
“V1”: Volume of the box
“P2”: Intrathoracic pressure, generated by the patient
“V2”: Calculated volume of patient’s thoracic cavity.
- By using Boyle’s Law  test provides a measure of FUCTIONAL RESIDUAL
CAPACITY(FRC)
 LUNG VOLUMES include:
1. TIDAL VOLUME(TV)
2. INSPIRATORY RESERVE VOLUME(IRV)
3. EXPIRATORY RESERVE VOLUME(ERV)
4. RESIDUAL VOLUME(RV)
• LUNG CAPACITIES include:
1. INSPIRATORY CAPACITY(IC)
2. EXPIRATORY CAPACITY(EC)
3. VITAL CAPACITY(VC)
4. FUNCTIONAL RESIDUAL CAPACITY(FRC)
5. TOTAL LUNG CAPACITY(TLC)
LUNG VOLUMES
1. TIDAL VOLUME(TV):
- “Amount of air inhaled & exhaled at rest”
- TV = 0.5 litres
2. INSPIRATORY RESERVE VOLUME(IRV):
- “Additional volume of air, that a person can inhale (via forceful inspiration)”
- IRV = 3.1 litres
3. EXPIRATORY RESERVE VOLUME(ERV):
- “Additional volume of air, that a person can exhale(via forceful exhalation)”
- ERV = 1.2 litres.
4. RESIDUAL VOLUME(RV):
- “Volume of air remaining in the lung, even after forceful exhalation”
- RV = 1.2 litres
LUNG CAPACITIES
1. INSPIRATORY CAPACITY(IC):
- “Total volume of air a person can inspire after normal expiration”
- IC = (TV + IRV) = (0.5 + 3.1 ) litres = 3.6 litres.
2. EXPIRATORY CAPACITY(EC):
- “Total volume of air a person can expire after normal inspiration”
- EC = (TV + ERV) = (0.5 + 1.2) litres = 1.7 litres
3. VITAL CAPACITY(VC):
- VC = (ERV + TV + IRV) = (1.2 + 0.5 + 3.1) litres = 4.8 litres.
4. FUNCTIONAL RESIDUAL CAPACITY(FRC):
- “Volume of air remaining inside lungs after normal expiration”
- FRC = (ERV + RV) = (1.2 + 1.2) litres = 2.4 litres.
5. TOTAL LUNG CAPACITY(TLC):
- “Total amount of air contained in the lungs after maximal inhalation”
- TLC = (RV + ERV + TV + IRV) = (1.2 + 1.2 + 0.5 + 3.1) litres = 6 litres.
DIFFUSION CAPACITY TESTS
 Gas exchange tests  help to measure ability of gases to diffuse across alveolar-
capillary membrane
 Useful in assessing INTERSTITIAL LUNG DISEASES
 Tests  measure “PER MINUTE TRANSFER OF CO, FROM ALVEOLI TO
BLOOD”
 Why is CO USED??
- CO is a gas that is uncommon inside the lung
- It has HIGH AFFINITY for HEMOGLOBIN in RBCs!!
• In the following conditions, diffusion capacity may be lessened:
a. Reduced surface area of alveoli
b. Thickening of alveolar-capillary membrane(due to infiltration of inflammatory
cells/ fibrotic changes)
Diffusion capacity of lungs to CO (DLCO) can be measured by either of the
following tests:
A. SINGLE BREATH TEST:
- In this test  patient deeply inhales (upto vital capacity) , a mixture of 0.3 % CO,
10% helium & air  patient is asked to hold breath for 10 seconds  patient
exhales fully  concentration of C0 & HELIUM are measured (during the end of
expiration)
- The concentration, so got  compared with inspired concentration  helps to
determine the amount diffusing across alveolar membrane
- Mean value for CO : 25-30 ml/min/ mm Hg
B. STEADY-STATE TEST:
- In this test  patient breathes 0.1-0.2% concentration of CO for 5-6 minutes
- In the final 2 minutes  expired gases are collected  ABG is obtained
- Expired gas  analyzed for total volume and concentrations of CO, CO2 & O2
- ABG  analyzed for CO2
- Above values are used to calculate amount of gas transferred across alveolar
membrane per unit of time
- Females may have slightly lower values than males(due to slightly smaller lung
volumes in the former)
 As said before  diffusion capacity tests are used to assess gas exchange
 Diffusion capacity is decreased in diseases that cause ALVEOLAR FIBROTIC
CHANGES, that include:
A. IDIOPATHIC CHANGES:
- Sarcoidosis
- Environmental/occupational disease(asbestosis, silicosis)
B. INDUCED CHANGES:
- Drugs (NTU, amiodarone, bleomycin).
AIRWAY REACTIVITY TESTS
Include:
A. BRONCHODILATOR STUDIES:
- In this test  patient is asked to perform spirometry IMMEDIATELY BEFORE
& 15-30 MINUTES AFTER administration of an INHALED SHORT-ACTING
BETA-2 ADRENERGIC AGONIST
- According to ATS guidelines  there will be a positive bronchodilator response,
signified by an improvement of:
i. FEV1 by 12%
ii. FVC by 200 mL.
B. BRONCHOPROVOCATION CHALLENGE TESTING:
- Also known as Bronchial provocation testing(BPT)
- Measures reactivity of airways to known concentrations of AGENTS that
INDUCE AIRWAY NARROWING
- In this test  airways are challenged with increasing doses of provocative
agents, like:
i. Methacholine
ii. Histamine
iii. Adenosine
iv. Specific allergens
- Used to aid in the diagnosis of asthma(in conditions, where symptom history/
spirometry with reversibility, cannot confirm/ reject the diagnosis)
- Also helpful for studying the effect of drug therapy on airway hyperreactivity &
for research purposes.
C. EXERCISE CHALLENGE TESTING:
• Exercise-induced bronchospasm(EIB)  occurs in majority of asthmatic patients
• Rapid breathing during exercise  causes cooling & drying of airways  can
lead to EIB
• Test is done to:
i. Confirm/ rule out EIB
ii. Evaluate effectiveness of medications used to treat/prevent EIB.
• Duration of exercise is AGE & TOLERANCE dependent
• Children < 12 years of age  usually take 6 minutes
• Older children & adults  take 8 minutes to complete the test.
• After the exercise is completed  patient does “SERIAL SPIROMETRY”, at 5-
minute intervals, for 20-30 minutes  FEV1 is monitored
• A 10-15% decline in FEV1 from baseline  generally accepted as “abnormal
response”.
EXERCISE CHALLENGE TESTS USED FOR SCREENING
EIB:
METHOD ADVANTAGES DISADVANTAGES
Exercise bicycle Easily standardized, portable Relatively expensive
Treadmill Easily standardized Expensive
Free-running asthma screening
test
Familiar, inexpensive, most
asthmogenic
Not standardized, demerits of
running for 6-7 minutes, space
requirements.
Randolph C. Exercise-induced asthma: update on pathophysiology, clinical diagnosis, and treatment. Curr Probl Pediatr 1997;27:57.
SIX-MINUTE WALK TEST
- Test used to measure the distance a patient can walk on a FLAT, HARD
SURFACE in 6 minutes.
- Helps to predict morbidity & mortality for patients with CHF, COPD &
pulmonary HTN
- In this test  patient is asked to WALK AS FAR AS POSSIBLE for 6 minutes
- Stopping & resting is allowed during the test
- Normal values include:
a. For ADULTS: 500-630 metres
b. For CHILDREN: 470 +/- 59 metres
- Contraindications include:
a. UA
b. MI (in past 1 month)
c. BP > 180/100 mm Hg!
 To be precise  6MWT is used to assess amount of oxygen required for exertion
 Patients with mild-moderate pulmonary disease may have normal oxygen
saturation at rest, but POOR SATURATION with EXERTION
 If oxygen saturation is 88% or lower  it requires need for supplemental
oxygenation!
THANK YOU!!!

More Related Content

PPTX
Drug induced pulmonary diseases
PPTX
Pulmonary Function Testing-Simplified description...!
PPTX
Pulmonary Function Test's
PPTX
a detailed study on pulmonary function test
PPTX
pulmonary function test
PPT
Lung fuction tests
PDF
pulmonary Function Test Interpreation
PPTX
Interpretation of Pulmonary Function Test
Drug induced pulmonary diseases
Pulmonary Function Testing-Simplified description...!
Pulmonary Function Test's
a detailed study on pulmonary function test
pulmonary function test
Lung fuction tests
pulmonary Function Test Interpreation
Interpretation of Pulmonary Function Test

What's hot (20)

PPTX
New advances in ild 27 feb f
PPTX
Pharmacoeconomics
PPTX
pulmonary function tests ppt
PPT
PPTX
Pharmacokinetic Drug Interactions
PDF
Extracorporeal removal of drugs
PPTX
HEALTH SCREENING SERVICES
PDF
Statistical softwares used in pharmacoeconomics @ RxVichuZ!! :)
PPTX
Collateral ventilation
PPTX
Dosing in obese patient
PPTX
Effects of liver diseases on pharmacokinetics
PPTX
Copd management
PPT
Interpretation OF PFT
PPT
Interpretation of CPET
PPTX
Lung resection
PDF
Diagnosis of COPD
PPTX
Individualization of dosage regimen
PPTX
Pulmonary function test
PPTX
EFFECT OF HEPATIC DISEASE ON PHARMACOKINETICS.pptx
DOCX
Adaptive method OR dosing with feedback
New advances in ild 27 feb f
Pharmacoeconomics
pulmonary function tests ppt
Pharmacokinetic Drug Interactions
Extracorporeal removal of drugs
HEALTH SCREENING SERVICES
Statistical softwares used in pharmacoeconomics @ RxVichuZ!! :)
Collateral ventilation
Dosing in obese patient
Effects of liver diseases on pharmacokinetics
Copd management
Interpretation OF PFT
Interpretation of CPET
Lung resection
Diagnosis of COPD
Individualization of dosage regimen
Pulmonary function test
EFFECT OF HEPATIC DISEASE ON PHARMACOKINETICS.pptx
Adaptive method OR dosing with feedback
Ad

Similar to Pulmonary function tests: A brief Insight- By RxVichuZ! :) (20)

PPTX
Pulmonary fuction test seminar
PPTX
Pulmonary Function Testing (PFT): Procedures, Interpretation & Clinical Appli...
PPT
Pulmonary function tests
PPTX
Common pulmonary functions and interpretation
PPT
Introduction to Pulmonary function test
PPTX
Pulmonary Function Tests-Nursing Maseno.pptx
PPTX
Spirometry Basics
PPTX
PULMONARY FUNCTION TEST (PFT)_ 082147.pptx
PDF
Bedside pft 1
PPTX
pulmonary function tests
PDF
Pulmonary function testing (spirometry )
PPTX
pulmonary functions test powerpoint.pptx
PPT
Pulmonary Function Testing
PPT
Anaecon India - Spirometery
PPTX
PULMONARY FUNCTION TESTS - LAB DATA INTERPRETATION
PPTX
Demo Cum Lecture on the topic of Spirometry by Pandian M, Tutor, Dept. of Phy...
PPTX
Pft 10.12.14
PPTX
Pulmonary function tests
DOCX
Respiratory volumes & abnormalities
PPTX
PFT JJDWIJDWJWDIJIWDJIWJDIWJIDJIWJIDIWJIDJWIJD
Pulmonary fuction test seminar
Pulmonary Function Testing (PFT): Procedures, Interpretation & Clinical Appli...
Pulmonary function tests
Common pulmonary functions and interpretation
Introduction to Pulmonary function test
Pulmonary Function Tests-Nursing Maseno.pptx
Spirometry Basics
PULMONARY FUNCTION TEST (PFT)_ 082147.pptx
Bedside pft 1
pulmonary function tests
Pulmonary function testing (spirometry )
pulmonary functions test powerpoint.pptx
Pulmonary Function Testing
Anaecon India - Spirometery
PULMONARY FUNCTION TESTS - LAB DATA INTERPRETATION
Demo Cum Lecture on the topic of Spirometry by Pandian M, Tutor, Dept. of Phy...
Pft 10.12.14
Pulmonary function tests
Respiratory volumes & abnormalities
PFT JJDWIJDWJWDIJIWDJIWJDIWJIDJIWJIDIWJIDJWIJD
Ad

More from RxVichuZ (20)

PPTX
Parkinson Disease Pathophysiology #Dr. Vishnu!
PPT
HIV Pathophysiology, by Dr. Vishnu
PPT
General principles involved in management of poisoning (Part 1)
PPTX
Buprenorphine drug profile by Dr. Vishnu!
PDF
5-Alpha reductase inhibitors drug profile
PDF
Rational use of antibiotics by RxVichuZ!
PDF
Co-trimoxazole drug profile by RxVichuZ!
PDF
Amoxicillin drug profile: By RxVichuZ! :)
PPTX
Food drug interactions with penicillins: by RxVichuZ!
PPTX
Snake bite poisoning and its treatment by RxVichuZ!
PPTX
Case study on Heart Failure by RxVichuZ!
PPTX
Directly acting antivirals and Visceral Leishmaniasis: A case report
PPTX
Drug mnemonics; by RxVichuZ! ;)
PPTX
Acute coronary syndrome management by RxVichuZ! ;)
PPTX
RNTCP guidelines for tuberculosis management: Extended version
PPTX
Journal club presentation: by RxVichuZ!! ;)
PPTX
PPI-INDUCED BICYTOPENIA: MATTER OF CONCERN by RxVichuZ! ;)
PPTX
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insight
PPTX
Principles of cancer chemotherapy: a deep insight by RxVichuZ!
PPTX
Sulfonylureas for Diabetes: A deep insight
Parkinson Disease Pathophysiology #Dr. Vishnu!
HIV Pathophysiology, by Dr. Vishnu
General principles involved in management of poisoning (Part 1)
Buprenorphine drug profile by Dr. Vishnu!
5-Alpha reductase inhibitors drug profile
Rational use of antibiotics by RxVichuZ!
Co-trimoxazole drug profile by RxVichuZ!
Amoxicillin drug profile: By RxVichuZ! :)
Food drug interactions with penicillins: by RxVichuZ!
Snake bite poisoning and its treatment by RxVichuZ!
Case study on Heart Failure by RxVichuZ!
Directly acting antivirals and Visceral Leishmaniasis: A case report
Drug mnemonics; by RxVichuZ! ;)
Acute coronary syndrome management by RxVichuZ! ;)
RNTCP guidelines for tuberculosis management: Extended version
Journal club presentation: by RxVichuZ!! ;)
PPI-INDUCED BICYTOPENIA: MATTER OF CONCERN by RxVichuZ! ;)
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insight
Principles of cancer chemotherapy: a deep insight by RxVichuZ!
Sulfonylureas for Diabetes: A deep insight

Recently uploaded (20)

PPTX
Important Obstetric Emergency that must be recognised
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PPTX
Uterus anatomy embryology, and clinical aspects
PPT
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
PPTX
Respiratory drugs, drugs acting on the respi system
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
DOCX
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
PPTX
Slider: TOC sampling methods for cleaning validation
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
PPTX
SKIN Anatomy and physiology and associated diseases
PPTX
surgery guide for USMLE step 2-part 1.pptx
PPT
ASRH Presentation for students and teachers 2770633.ppt
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PPTX
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
PPTX
post stroke aphasia rehabilitation physician
PDF
Human Health And Disease hggyutgghg .pdf
PPTX
History and examination of abdomen, & pelvis .pptx
PPTX
Imaging of parasitic D. Case Discussions.pptx
PPTX
Neuropathic pain.ppt treatment managment
PPT
Obstructive sleep apnea in orthodontics treatment
Important Obstetric Emergency that must be recognised
Medical Evidence in the Criminal Justice Delivery System in.pdf
Uterus anatomy embryology, and clinical aspects
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
Respiratory drugs, drugs acting on the respi system
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
Slider: TOC sampling methods for cleaning validation
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
SKIN Anatomy and physiology and associated diseases
surgery guide for USMLE step 2-part 1.pptx
ASRH Presentation for students and teachers 2770633.ppt
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
post stroke aphasia rehabilitation physician
Human Health And Disease hggyutgghg .pdf
History and examination of abdomen, & pelvis .pptx
Imaging of parasitic D. Case Discussions.pptx
Neuropathic pain.ppt treatment managment
Obstructive sleep apnea in orthodontics treatment

Pulmonary function tests: A brief Insight- By RxVichuZ! :)

  • 1. PRESENTED BY: VISHNU.R.NAIR, 5TH YEAR PHARM.D, NATIONAL COLLEGE OF PHARMACY(NCP).
  • 3. Refer to tests, that provide OBJECTIVE & QUANTIFIABLE measures of LUNG FUNCTION Useful in the DIAGNOSIS, EVALUATION & MONITORING of respiratory disease/s Also help to evaluate : a. Response/ efficacy of ongoing therapy b. Side-effects of medications, that lead to pulmonary disease.
  • 5.  Include: A. DIAGNOSIS: - Clinical manifestations of respiratory disease - Follow-up of historical/lab findings - Disease effects on pulmonary function - Drug-induced pulmonary disorders. B. EVALUATION: - Medico-legal issues - Rehabilitation
  • 6. C. MONITORING: - Respiratory disease progression - Prognosis - Occupational/ environmental exposure to toxins - Therapeutic drug effectiveness - Drug effects on pulmonary function.
  • 8. - Test, that measures various aspects of breathing & lung function - Standardization of spirometry  regulated by ATS & ERS guidelines - PROCEDURE OF SPIROMETRY: a. Patient  asked to breathe into a tube(mouth piece) b. Mouth piece  connected to a machine(spirometer) c. Spirometer  measures amount & flow of inhaled/ exhaled air d. Physical forces of airflow + total amount of air inhaled/exhaled  converted by transducers to electrical signals  displayed on a computer screen e. Prior to conducting spirometry  the technique involved SHOULD BE EXPLAINED & DEMONSTRATED TO THE PATIENT f. Since spirometry results  depend on patient’s inhalation & exhalation  importance of COMPLETELY FILLING & EMPYTING THE LUNGS OF AIR during the test should be emphasized!! g. Nose clips should be worn during the test(to prevent air loss through nose!)
  • 10. - There are 2 types of SPIROMETRY SYSTEMS: A. OPEN-CIRCUIT SYSTEM: - In this  patient has to INHALE BEFORE INSERTING THE MOUTH-PIECE B. CLOSED-CIRCUIT SYSTEM: - In this  mouthpiece is first inserted  patient takes several normal breaths, before airflow is measured
  • 11. - There are 2 TYPES of SPIROMETRY: A. STATIC SPIROMETRY: - Test, that is “VOLUME-BASED” & “SLOW” B. DYNAMIC SPIROMETRY: - Test, that is “TIME-BASED” - Flow-dependant - “FORCED”!!
  • 13. Include: 1. VITAL CAPACITY(VC) 2. FORCED EXPIRATORY VOLUME(FEV) 3. FORCED EXPIRATORY FLOW(FEF) - Via SPIROMETRY  above values, & a FLOW-VOLUME CURVE are obtained - FLOW-VOLUME CURVE: a. Graphical representation of INSPIRATION & EXPIRATION b. Also known as “flow-volume loops”.
  • 14. VITAL CAPACITY: - Includes: a. FORCED VITAL CAPACITY(FVC) b. SLOW VITAL CAPACITY(SVC) - FVC  refers to total volume of air EXHALED as HARD & as FAST as possible after a MAXIMAL INHALATION - Obtained from “DYNAMIC SPIROMETRY” - SVC  refers to total volume of air EXHALED as SLOW as possible, after a MAXIMAL INHALATION - SVC  obtained from “STATIC SPIROMETRY”.
  • 15. - In patients with NORMAL AIRWAY FUNCTION  FVC & SVC are usually similar - In COPD patients  there is trivial divergence! - During initial stages of COPD  FVC decreases before SVC does!
  • 16. FORCED EXPIRATORY VOLUME: - Refers to the assessment of how much air a person can exhale during a FORCED BREATH. - Amounts of air exhaled may be measured after: a. FEV0.5: 0.5 seconds b. FEV1: 1 second(clinically significant, indicator of airway function!) c. FEV3: 3 seconds d. FEV6: 6 seconds, respectively. - FEV1/FVC ratio  used to estimate presence & amount of obstruction inside airways - In normal individuals  exhalation is approximately 50 % of their FVC in the first 0.5 seconds, 80% in 1 second & 98 % in 3 seconds. - In patients with OBSTRUCTIVE DISEASE  there is a decreased ratio (ratio varies based on obstruction severity).
  • 17. - According to ATS(American Thoracic Society), EPS(European Respiratory Society) & GOLD(Global Initiative for Chronic Obstructive Lung Disease) guidelines  the following criteria is given for diagnosis & severity grading of COPD: a. If FEV1/FVC ratio < 70%  indicates chronic obstruction(DIAGNOSIS) b. For SEVERITY GRADING  FEV1 values are noted: • If FEV1 ≥ 80% : Mild-severity • If FEV1 = 50-80% : Moderate severity • If FEV1= 30-50% : Severe form of disease • If FEV1< 30% : Very severe form of disease, respiratory failure.
  • 18. FORCED EXPIRATORY FLOW: - Measures AIRFLOW RATE during FORCED EXPIRATION - Used to measure: a. Flow of air in medium & small airways(bronchioles & terminal bronchioles) b. To check for large obstructions in terminal bronchioles (as in acute severe asthma).
  • 19. PEAK EXPIRATORY FLOW RATE: - Also known as “peak flow” - Occurs within first milliseconds of expiratory flow - Measures maximum airflow rate - Measured using PEAK FLOW METERS - Applications: a. To evaluate for large airway obstruction b. To determine severity of asthma exacerbation - PEFR  preferred over SPIROMETRY during exacerbation preferential benefit!!!
  • 20. DISEASE FEV1/FVC FEV1 FVC RV TLC COPD Decreased Decreased Normal/decrease d Normal/Increase d Normal/Increase d Obstructive Lung Disease(Reversi ble & Stable) Normal Normal Normal Normal Normal Restrictive Lung Disease Normal/Increase d Decreased Decreased Decreased Decreased Combined Obstructive & Restrictive Decreased/norm al Decreased Decreased Increased, normal/decrease d Decreased
  • 22.  Body plethysmography  refers to the method used to obtain LUNG VOLUME MEASURES  Lung volumes  indicate the amount of gas present in the lungs at various stages of inflation  In body plethysmography  patient is asked to sit inside an airtight box  asked to inhale & exhale against a closed shutter  Inside the box  there will be a PRESSURE TRANSDUCER  PRESSURE TRANSDUCER  measures pressure changes within the box during respiration  In other words  transducer measures the intrathoracic pressure generated when the patient rapidly & forcefully puffs against the closed mouthpiece!!!
  • 24. - Above obtained details  interpreted into Boyle’s Law: “ P1 * V1 = P2 * V2”, where “P1”: Pressure inside the box, when the patient is seated(atmospheric pressure) “V1”: Volume of the box “P2”: Intrathoracic pressure, generated by the patient “V2”: Calculated volume of patient’s thoracic cavity. - By using Boyle’s Law  test provides a measure of FUCTIONAL RESIDUAL CAPACITY(FRC)
  • 25.  LUNG VOLUMES include: 1. TIDAL VOLUME(TV) 2. INSPIRATORY RESERVE VOLUME(IRV) 3. EXPIRATORY RESERVE VOLUME(ERV) 4. RESIDUAL VOLUME(RV) • LUNG CAPACITIES include: 1. INSPIRATORY CAPACITY(IC) 2. EXPIRATORY CAPACITY(EC) 3. VITAL CAPACITY(VC) 4. FUNCTIONAL RESIDUAL CAPACITY(FRC) 5. TOTAL LUNG CAPACITY(TLC)
  • 27. 1. TIDAL VOLUME(TV): - “Amount of air inhaled & exhaled at rest” - TV = 0.5 litres 2. INSPIRATORY RESERVE VOLUME(IRV): - “Additional volume of air, that a person can inhale (via forceful inspiration)” - IRV = 3.1 litres 3. EXPIRATORY RESERVE VOLUME(ERV): - “Additional volume of air, that a person can exhale(via forceful exhalation)” - ERV = 1.2 litres.
  • 28. 4. RESIDUAL VOLUME(RV): - “Volume of air remaining in the lung, even after forceful exhalation” - RV = 1.2 litres
  • 30. 1. INSPIRATORY CAPACITY(IC): - “Total volume of air a person can inspire after normal expiration” - IC = (TV + IRV) = (0.5 + 3.1 ) litres = 3.6 litres. 2. EXPIRATORY CAPACITY(EC): - “Total volume of air a person can expire after normal inspiration” - EC = (TV + ERV) = (0.5 + 1.2) litres = 1.7 litres 3. VITAL CAPACITY(VC): - VC = (ERV + TV + IRV) = (1.2 + 0.5 + 3.1) litres = 4.8 litres.
  • 31. 4. FUNCTIONAL RESIDUAL CAPACITY(FRC): - “Volume of air remaining inside lungs after normal expiration” - FRC = (ERV + RV) = (1.2 + 1.2) litres = 2.4 litres. 5. TOTAL LUNG CAPACITY(TLC): - “Total amount of air contained in the lungs after maximal inhalation” - TLC = (RV + ERV + TV + IRV) = (1.2 + 1.2 + 0.5 + 3.1) litres = 6 litres.
  • 33.  Gas exchange tests  help to measure ability of gases to diffuse across alveolar- capillary membrane  Useful in assessing INTERSTITIAL LUNG DISEASES  Tests  measure “PER MINUTE TRANSFER OF CO, FROM ALVEOLI TO BLOOD”  Why is CO USED?? - CO is a gas that is uncommon inside the lung - It has HIGH AFFINITY for HEMOGLOBIN in RBCs!! • In the following conditions, diffusion capacity may be lessened: a. Reduced surface area of alveoli b. Thickening of alveolar-capillary membrane(due to infiltration of inflammatory cells/ fibrotic changes)
  • 34. Diffusion capacity of lungs to CO (DLCO) can be measured by either of the following tests: A. SINGLE BREATH TEST: - In this test  patient deeply inhales (upto vital capacity) , a mixture of 0.3 % CO, 10% helium & air  patient is asked to hold breath for 10 seconds  patient exhales fully  concentration of C0 & HELIUM are measured (during the end of expiration) - The concentration, so got  compared with inspired concentration  helps to determine the amount diffusing across alveolar membrane - Mean value for CO : 25-30 ml/min/ mm Hg
  • 35. B. STEADY-STATE TEST: - In this test  patient breathes 0.1-0.2% concentration of CO for 5-6 minutes - In the final 2 minutes  expired gases are collected  ABG is obtained - Expired gas  analyzed for total volume and concentrations of CO, CO2 & O2 - ABG  analyzed for CO2 - Above values are used to calculate amount of gas transferred across alveolar membrane per unit of time - Females may have slightly lower values than males(due to slightly smaller lung volumes in the former)
  • 36.  As said before  diffusion capacity tests are used to assess gas exchange  Diffusion capacity is decreased in diseases that cause ALVEOLAR FIBROTIC CHANGES, that include: A. IDIOPATHIC CHANGES: - Sarcoidosis - Environmental/occupational disease(asbestosis, silicosis) B. INDUCED CHANGES: - Drugs (NTU, amiodarone, bleomycin).
  • 38. Include: A. BRONCHODILATOR STUDIES: - In this test  patient is asked to perform spirometry IMMEDIATELY BEFORE & 15-30 MINUTES AFTER administration of an INHALED SHORT-ACTING BETA-2 ADRENERGIC AGONIST - According to ATS guidelines  there will be a positive bronchodilator response, signified by an improvement of: i. FEV1 by 12% ii. FVC by 200 mL.
  • 39. B. BRONCHOPROVOCATION CHALLENGE TESTING: - Also known as Bronchial provocation testing(BPT) - Measures reactivity of airways to known concentrations of AGENTS that INDUCE AIRWAY NARROWING - In this test  airways are challenged with increasing doses of provocative agents, like: i. Methacholine ii. Histamine iii. Adenosine iv. Specific allergens - Used to aid in the diagnosis of asthma(in conditions, where symptom history/ spirometry with reversibility, cannot confirm/ reject the diagnosis) - Also helpful for studying the effect of drug therapy on airway hyperreactivity & for research purposes.
  • 40. C. EXERCISE CHALLENGE TESTING: • Exercise-induced bronchospasm(EIB)  occurs in majority of asthmatic patients • Rapid breathing during exercise  causes cooling & drying of airways  can lead to EIB • Test is done to: i. Confirm/ rule out EIB ii. Evaluate effectiveness of medications used to treat/prevent EIB. • Duration of exercise is AGE & TOLERANCE dependent • Children < 12 years of age  usually take 6 minutes • Older children & adults  take 8 minutes to complete the test. • After the exercise is completed  patient does “SERIAL SPIROMETRY”, at 5- minute intervals, for 20-30 minutes  FEV1 is monitored • A 10-15% decline in FEV1 from baseline  generally accepted as “abnormal response”.
  • 41. EXERCISE CHALLENGE TESTS USED FOR SCREENING EIB: METHOD ADVANTAGES DISADVANTAGES Exercise bicycle Easily standardized, portable Relatively expensive Treadmill Easily standardized Expensive Free-running asthma screening test Familiar, inexpensive, most asthmogenic Not standardized, demerits of running for 6-7 minutes, space requirements. Randolph C. Exercise-induced asthma: update on pathophysiology, clinical diagnosis, and treatment. Curr Probl Pediatr 1997;27:57.
  • 43. - Test used to measure the distance a patient can walk on a FLAT, HARD SURFACE in 6 minutes. - Helps to predict morbidity & mortality for patients with CHF, COPD & pulmonary HTN - In this test  patient is asked to WALK AS FAR AS POSSIBLE for 6 minutes - Stopping & resting is allowed during the test - Normal values include: a. For ADULTS: 500-630 metres b. For CHILDREN: 470 +/- 59 metres - Contraindications include: a. UA b. MI (in past 1 month) c. BP > 180/100 mm Hg!
  • 44.  To be precise  6MWT is used to assess amount of oxygen required for exertion  Patients with mild-moderate pulmonary disease may have normal oxygen saturation at rest, but POOR SATURATION with EXERTION  If oxygen saturation is 88% or lower  it requires need for supplemental oxygenation!